Cytokinetics Incorporated (CYTK)
NASDAQ: CYTKHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CYTK stock chart
Technical analysisKey statistics
All statistics- Market cap
- $7.07B
- EPS (TTM)
- -$6.02
- Dividend yield
- None
- 52-week range
- 50.32 – 88.31
- Day range
- 50.60 – 53.38
- Volume / Avg
- 1.43M / 2.02M
- Beta
- —
- Shares outstanding
- 139.30M
52-week range
CYTK stock today
Cytokinetics (CYTK) closed at $50.78 on Nov 20, down 1.32% (-$0.68), versus the S&P 500's 3.70% decline. Shares are 42.5% below their 52-week high of $88.31, set on Jun 30, 2026 and 0.9% above the 52-week low of $50.32, near the bottom of the past year's range. CYTK is down 20.1% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 22.4%.
Cytokinetics has posted a net loss over the last twelve months (EPS of -$6.02), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Cytokinetics
Company profileCytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Robert I. Blum
- Headquarters
- South San Francisco, CA
- Employees
- 673
- IPO year
- 2004
- Website
- cytokinetics.com
Financial highlights
Full financialsIn fiscal 2025, Cytokinetics generated $88.0 million in revenue, up 376.6% from fiscal 2024, its 2nd consecutive year of revenue growth. Cytokinetics reported a net loss of $785.0 million, compared with a loss of $589.5 million a year earlier. Operating margin was -695.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $88.04M | $18.47M | $7.53M | $94.59M | $70.43M |
| Growth | +376.56% | +145.34% | -92.04% | +34.30% | +26.15% |
| Net income | $-784.96M | $-589.53M | $-526.24M | $-388.95M | $-215.31M |
| EPS (diluted) | $-6.54 | $-5.26 | $-5.45 | $-4.33 | $-2.80 |
Analyst forecast
ForecastConsensus (22 analysts)
strong_buy
Avg. price target
$109.42+115.48%
- Strong buy 7
- Buy 13
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-1.37 vs $-1.50
- Surprise
- +8.67%
CYTK news
All CYTK news- Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCMGlobeNewswire
- Can BMY Sustain Growth in Its Cardiovascular Franchise?NasdaqBMY, CYTK, EWTX
- Notable Thursday Option Activity: CYTK, LUNR, LOPENasdaqCYTK, LUNR, LOPE
- Cytokinetics Announces Additional Data Related to Aficamten Presented at the Hypertrophic Cardiomyopathy Medical Society (HCMS) Scientific Sessions Held in Collaboration with the American Heart Association Scientific Sessions 2026GlobeNewswire
- Cytokinetics (CYTK) Q3 2026 Earnings Call TranscriptNasdaq
- Cytokinetics outlines >50% new-to-brand share goal by year-end as MYQORZO expands into the U.K. this quarterSeeking Alpha
- Cytokinetics Reports Third Quarter 2026 Financial Results and Provides Business UpdateNasdaq
Cytokinetics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| AMRXAmneal Pharmaceuticals Inc. Class A | 21.12 | -1.26% | $7.36B | vs CYTK |
| CORTCorcept Therapeutics Incorporated | 63.62 | -2.09% | $6.96B | vs CYTK |
| KNSAKiniksa Pharmaceuticals International plc Class A | 93.90 | +0.38% | $7.38B | vs CYTK |
| AXSMAxsome Therapeutics Inc. | 129.36 | -4.66% | $6.80B | vs CYTK |
| ALKSAlkermes plc | 44.94 | -2.69% | $7.55B | vs CYTK |
| RYTMRhythm Pharmaceuticals Inc. | 112.36 | -3.80% | $7.79B | vs CYTK |
| PTGXProtagonist Therapeutics Inc. | 121.40 | -2.11% | $7.92B | vs CYTK |
| ABVXAbivax SA ADR | 73.20 | -9.24% | $6.41B | vs CYTK |
Indexes, lists and sector
Cytokinetics stock FAQ
What is Cytokinetics's stock price today?
CYTK last traded at $50.78 as of Nov 20, 4:00 PM EST, down 1.32% on the day. Prices are delayed at least 15 minutes.
Does Cytokinetics pay a dividend?
No. Cytokinetics does not currently pay a regular cash dividend.
Who is Cytokinetics's CEO?
Mr. Robert I. Blum is the chief executive officer of Cytokinetics Incorporated, which has about 673 employees.
Has CYTK ever split its stock?
Yes. The most recent CYTK stock split was a 1-for-6 split on Jun 25, 2013.
What is the CYTK 52-week high?
The 52-week high for CYTK is $88.31 and the 52-week low is $50.32. The stock is currently 42.5% below its high.